


PHARMACEUTICAL 2023

Celularity Inc Rank 189 of 446







PHARMACEUTICAL 2023

Celularity Inc Rank 189 of 446



The relative strengths and weaknesses of Celularity Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celularity Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 130% points. The greatest weakness of Celularity Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 75% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	33,502
Cost of Goods Sold	0
Intangible Assets	240,688
Liabilities, Current	62,088
Liabilities, Non-Current	30,525
Other Assets	51,221
Other Compr. Net Income	9.0
Other Expenses	-100,796
Other Liabilities	109,552
Other Net Income	39,805
Other Revenues	17,975
Property and Equipment	75,655
Research and Development	78,363
Selling, General and Administrative Expense	66,021

Output Variable	Value in 1000 USD
Assets	401,066
Liabilities	202,165
Expenses	43,588
Revenues	17,975
Stockholders Equity	198,901
Net Income	14,192
Comprehensive Net Income	14,196
Economic Capital Ratio	118%

